Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Foscan photodynamic therapy for non-resectable bile duct carcinoma
2005-004866-17Phase 2Completed
- Sponsor
- Paracelsus Medical University Department of Medicine I
- Start
- Nov 2005
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temoporfin in cholangiocarcinoma (CCA), sponsored by Paracelsus Medical University Department of Medicine I. Primary endpoints: Rate of local response and Depth of tumoricidal tissue penetration. Started Nov 2005; status: completed.
02
Drugs
temoporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2005-004866-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004866-17.